Contract services firm Almac aims to expand its trial patient management and compliance offering though a new partnership with ePRO specialist Exco InTouch.
CRO and Pharma patient recruitment efforts can benefit from social networks and online patient groups, but clarification from the US FDA is still needed.
Agilent Technolgies, the Santa Clara, US-based scientific instrument manufacturer, has acquired instrument manufacturer and contract research organisation (CRO), Biocius Life Sciences, for an undisclosed amount.
A global compulsory register of all contractors and subcontractors involved in each clinical trial should be created to increase transparency, according to a study.
PPD and Charles River Laboratories (CRL) finished 2010 with very different quarters, each posting results that illustrate trends within the CRO sector.
Lab Research has signed a non-binding letter of intent (LOI) with a US private equity group interested in acquiring the preclinical contract research organisation (CRO).
US CRO the Duke Clinical Research Institute (DCRI) has teamed up with Kaplan EduNeering to develop a training programme to meet rising global demand for qualified clinical researchers.
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
US CRO INC Research has bought industry consulting group Avos Life Sciences, citing pharma clients’ need to maximize return on R&D and minimize risk as the key driver.
PharmaNet has launched its Initiator data capture and PKS analysis platforms in a bid to speed up data acquisition and processing of Phase I trial reports.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including the departure of Patheon’s CEO and a number of promotions at Covance.
Newly-formed Gateway Analytical is confident its service offering, employees’ experience and ties to its parent company will allow it to grow despite a challenging operating environment.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Premier Research, Porsolt and BioStorage.
An academic clinical research centre that claims CROs markedly increase costs and reduce trial monitoring to box ticking, statements disputed by ACRO, has described its adoption of an in-house system.
Synteract is to hire up to 30 additional staff by the end of 2011 to work at its recently expanded site in Research Triangle Park (RTP), North Carolina, US.
PPD signs clinical imaging and formulation development collaborations, reorganises reporting units and cites “improved performance in emerging markets” and spending controls as key to third quarter gains.
Icon reported a two per cent rise in Q3 net revenue, but saw profits dwindle in its central lab business after a growing backlog of work failed to convert to revenue as quickly as expected.
Advanced cardiovascular and metabolic services will be provided to biopharm by a strategic collaboration between CROs Cardialysis and Sticares InterACT.
Patient recruiters and national regulators must learn from each other to better understand outreach tactics and how they fit with a country’s ethics and laws.
Retention strategies, trial site evaluations and dedicated budgets should be used to recruit patients to, and keep them in, clinical trials, according to research.
The Asia Pacific trial sector grew during the global economic downturn as sponsors sought to improve access to patients, cut costs and improve data quality according to Novotech CEO Alek Safarian.
Ockham looks east for patient recruitment, setting up partnership with Russlan Clinical Research (RCR) to increase access to in-demand clinical trial destination.
Preclinical CRO Lab Research says new contracts are a sign of continuing recovery in market as well as firm’s ability to attract broader clientele base.
Encorium has bought Progenitor International Research, furthering efforts to fix its financial woes by focusing on vaccines, oncology and growth in emerging markets.
